

New

Population

This recommendation applies only to people with these characteristics:



Interventions

Strong recommendations in favour

Weak or conditional recommendations in favour

For those with highest risk of hospital admission

Use the interactive multiple comparison tool to compare and choose treatments

MATCH-IT

Disease severity

Non-severe

Severe

Critical

Absence of signs of severe or critical disease

Oxygen saturation <90% on room air

Signs of pneumonia

Signs of severe respiratory distress

Requires life sustaining treatment

Acute respiratory distress syndrome

Sepsis

Septic shock

Corticosteroids

IL-6 receptor blockers

or

Baricitinib

Depending on availability as well as clinical and contextual factors

Nirmatrelvir and ritonavir

Molnupiravir

Mitigation strategies to reduce potential harms should be implemented

Sotrovimab





Remdesivir

Casirivimab and imdevimab

Casirivimab and imdevimab

Evidence of limited efficacy against Omicron BA1 variant

For those with seronegative status for SARS-CoV-2 antibodies

		New	
 Weak or conditional recommendations against	Corticosteroids	Ruxolitinib and tofacitinib Should be considered only if neither baricitinib nor IL-6 receptor blockers are available	
	Ivermectin	Should be considered only in the context of a clinical trial 	
		Convalescent plasma Should be considered only in the context of a clinical trial 	
 Strong recommendations against	Convalescent plasma		
		Hydroxychloroquine	
		Lopinavir-ritonavir	